Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159
Abstract
Immune-related radiological and biomarker monitoring in cancer immunotherapy trials permits interrogation of efficacy and reasons for therapeutic failure. We report the results from a cross-sectional analysis of response monitoring in 685 T-cell checkpoint-targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune-related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune-related response monitoring across cancer immunotherapy trials will improve analysis of outcomes and facilitate translational efforts to extend the benefit of immunotherapy to a greater proportion of patients with cancer.
Actions (login required)
 |
Administrator's edit/view item |